['plaque psoriasis']
['mirikizumab', 'placebo']

        Inclusion Criteria:

          -  Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of
             chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the
             following criteria:

               -  plaque psoriasis involving ≥10% body surface area (BSA) and absolute PASI score
                  ≥12 in affected skin at screening and baseline

               -  sPGA score of ≥3 at screening and baseline

          -  Candidate for biologic treatment for psoriasis.

        Exclusion Criteria:

          -  Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
             endocrine, hematological, neurological, or neuropsychiatric disorders or any other
             serious and/or unstable illness that, in the opinion of the investigator, could
             constitute a risk when taking investigational product or could interfere with the
             interpretation of data.

          -  Breastfeeding or nursing (lactating) women.

          -  Have had serious, opportunistic, or chronic/recurring infection within 6 months prior
             to screening.

          -  Have received live vaccine(s) (included attenuated live vaccines) within 1 month of
             screening or intend to during the study.

          -  Have any other skin conditions (excluding psoriasis) that would affect interpretation
             of the results.

          -  Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days
             prior to baseline.

          -  Have received topical psoriasis treatment within 14 days prior to baseline.

          -  Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17
             targeting biologics within 8 weeks prior to baseline.

          -  Have previous exposure to any biologic therapy targeting IL-23 (including
             ustekinumab), either licensed or investigational (previous briakinumab use is
             permitted).
      